Legend Biotech(LEGN) - 2022 Q2 - Quarterly Report

Exhibit 99.1 Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights On February 28, 2022, the U.S. Food and Drug Administration (FDA) approved CARVYKTI™ for the treatment of adults with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, marking the company's first product approved by a health authority. On May 26, 2022, the European Commiss ...